Abstract
We investigated the influence of the combined use of sizofiran, aβ-1,3-glucan and a recombinant interferon-γ (rIFN-γ) upon biological activities of peritoneal macrophages (Mφ). The number of peritoneal Mφ and the production of cytokines (interleukin-1β, interferon-γ and tumor necrosis factor) was increased by the combined treatment. Fully activated peritoneal Mφ based on the increased number of elongated pseudopods were observed by electromicroscope. Sizofiran seems to assure a sufficient supply of Mφ to kill tumor cells in the peritoneal cavity and co-administered rIFN-γ seems to directly stimulate the accumulated Mφ in addition to its direct cytotoxicity against tumor cells. This combination therapy may be a step to the prevention of the recurrence of gynecological malignancies including ovarian cancer, after a negative second-look laparotomy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- rIFN-γ :
-
recombinant interferon-γ
- IL-1β :
-
interleukin-1β
- TNF:
-
tumor necrosis factor
- SLL:
-
second look laparotomy
References
Cain JM, Saigo PE, Pierce VK, Clark DG, Jones WB, Smith DH, Hakes TB, Ochoa M, Lewis JL Jr. A review of second-look laparotomy for ovarian cancer. Gynecol Oncol 1986; 23, 14–25.
Podratz KC, Malkasian GD Jr, Wieand HS, Cha SS, Lee RA, Stanhope CR, Williams TJ. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988; 29, 274–82.
Ghatage P, Krepart GV, Lotocki R. Factor analysis of false-negative second-look laparotomy. Gynecol Oncol 1990; 36: 172–5.
Raju KS, McKinna JA, Barker GH, Wiltshaw E, Jones JM. Second-look operations in the planned management of advanced ovarian carcinoma. Am J Obstet Gynecol 1982; 144: 650–4.
Dauplat J, Ferriere JP, Gorbinet M, Legros M, Chollet P, Giraud B, Plagne R. Second-look laparotomy in managing epitherial ovarian carcinoma. Cancer 1986; 57, 1627–31.
Menczer J, Ben-Baruch G, Modan M, Brenner H. Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second-look laparotomy. Cancer 1989; 63: 1509–13.
Mahlck CG, Rogo KO, Stendahl U. Preliminary experience with intraperitoneal catheters in the treatment of ovarian cancer,in vovo 1991; 5: 119–22.
Matsuo T, Arika T, Mitani M, Komatsu N. Pharmacological and toxicological studies of a new antitumor polysaccharide, Schizophyllan. Arzneim-Forsch/Drug Res(I) 1982; 32: 647–56.
Tsuchiya Y, Igarashi M, Inoue M, Kumagai K. Cytokinerelated immuno-modulating activities of an anti-tumor glucan, sizofiran (SPG). J Pharmacobio-Dyn 1989: 12: 616–25.
Numasaki Y, Kikuchi M, Sugiyama Y, Ohba Y. A glucan, sizofiran: T cell adjuvant property and antitumor and cytotoxic macrophage inducing activities. Phrmacometrics 1990; 39: 39–48.
Okamura K, Suzuki M, Chihara T, Fujiwara A, Fukuda T, Goto S, Ichinohe K, Jimi S, Kasamatsu T, Kawai N, Mizuguchi K, Mori S, Nakano H, Noda K, Sekiba K, Suzuki K, Suzuki T, Takahashi K, Takeuchi K, Takeuchi S, Yajima A, Ogawa N. Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer: A randomized controlled study. Cancer 1986; 58: 865–72.
Noda K, Takeuchi S, Yajima A, Akiya K, Kasamatsu T, Tomoda Y, Ozawa M, Sekiba K, Sugimori H, Hashimoto S, Ogawa, N. Clinical effect of sizofiran combined with irradiation in cervical cancer patients: A randomized controlled study. Jpn J Clin Oncol 1992; 22, 17–25.
Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987; 236: 551–7.
Mannel DN, Falk W. Interferon-γ is required in activation of macrophages for tumor cytotoxicity. Cellular Immunology 1983; 79: 396–402.
Adams DO, Hamilton TA. Phagocytic cells: Cytotoxic activities of macrophages. In: Gallin JI, Goldstein IM, Synderman R, eds. Inflamation: Basic principles and clinical correlates. New York: Raven Press, 1988; 471–92.
Nathan CF. Secretory products of macrophages, J Clin Invest 1987; 79: 319–26.
Beutler B, Cerami A. Chachectin: more than a tumor necrosis factor. N Eng J Med 1987; 316: 379–85.
Baron S, Tyring S, Albrecht C, Fleischmann WR Jr, Klimpel G, Bennett A, Sarzotti R, Voss W. Complete cytolysis of cultured human tumor cells by interferon gamma treated human peripheral blood mononuclear leukocytes. In: Dianzani F, Rossi GB, eds. The Interferon System. New York: Raven Press, 1985: 333–41.
Belardelli F, Gresser I, Maury C, Mannoury, MT. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon resistant Friend leukemia cells. I Int J Cancer 1982; 30: 813–20.
D'Acquisto R, Markman M, Hakes T, Rubin S, Hoskins W, Lewis JL. A phase I trial of intraperitoneal recommbinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol 1988; 6: 689–95.
Stewart CC, Stevenson AP, Hibbs J. Effector mechanisms for macrophage-induced cytostasis and cytolysis of tumor cells. In: Heppner GH, Fulton AM, eds. Macrophages and Cancer. Florida: CRC Press, 1988: 39–59.
Chen JT, Hasumi K, Masubuchi K. Maintenance of the activation of peritoneal macrophages in the patients with ovarian cancer by sizofiran and recombinant interferon γ. Biotherapy 1992; 5: 137–43.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chen, J.T., Hasumi, K. Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-γ. Biotherapy 6, 189–194 (1993). https://doi.org/10.1007/BF01878080
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01878080